Zafgen's Research into Weight Loss Drug, Beloranib, Looks Promising

Zafgen announced in November results of a completed Phase 2 study of their obesity drug, Beloranib, in severely obese patients (non-pws). Findings from the study demonstrated significant weight loss in 147 obese individuals over a 12 weeks of treatment.
More recently, Zafgen shared results from a small trial involving 17 PWS adults. In the trial, the drug reduced weight and body fat as well as decreased the urge to food seek. Results from the Beloranib study have been reported in both the New York Times and Forbes magazine.

Stay Connected

Subscribe to FPWR News Updates

Heading 1

with a request body that specifies how to map the columns of your import file to the associated CRM properties in HubSpot.... In the request JSON, define the import file details, including mapping the spreadsheet's columns to HubSpot data. Your request JSON should include the following fields:... entry for each column.

February 13, 2014

Topics:

Research